AsseSSing Impact in pSoriatic Treatment (ASSIST)
Research type
Research Study
Full title
How does PsAID implementation affect treatment intensification and patient satisfaction in PsA?
IRAS ID
287039
Contact name
Laura Coates
Contact email
Sponsor organisation
University of Oxford, Clinical Trials and Research Governance
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Research Summary
This is an observational study recruiting adult patients with psoriatic arthritis (PsA) attending routine outpatients clinics in five countries (UK, France, Germany, Italy, Spain). The aim is to implement a new questionnaire which was developed with significant patient involvement which measures the impact of PsA across many different aspects of life (the PsA impact of disease or PsAID questionnaire). We will then test how this influences treatment decisions in routine practice, in addition to a number of other factors (disease activity, impact etc).
Summary of Results
The aim of the study was to use a relatively new questionnaire called the psoriatic arthritis impact of disease questionnaire (PsAID) in routine practice to see if it influences decisions about treatment. This questionnaire asks people to score many different ways that PsA can impact on their life. We wanted to see if this information might help people to discuss their disease with the doctors and nurses treating them. The study tested if the PsAID score influences treatment decision and will also test what other things also influence these decisions.
We recruited 503 participants from from 24 centres across five countries in Europe. Around half (49.1%) were female and their average age was 53. They were assessed in clinic between July 2021 and March 2022. 182 patients (36.2%) had treatment changed; treatment increase was the most common change (160 patients, 31.8%). In 22 of 24 sites, the average PsAID score for patients with treatment increase was higher than those with no treatment increase. There was a link between the PsAID score and treatment increase. For every increase in the PsAID score of 1 point, the odds of patients having their treatment increased was 58% higher. Other things were also linked with treatment increase including the use of non-biological (cheaper) treatments, poorer general health (as measured by EQ-VAS), increased swollen joint count and shorter disease duration.
We did find that the PsAID score was linked to the chance of treatment increase. The greater the PsAID score, the more likely an increase in treatment. But it was not just the PsAID score that was important. Many other things also influenced a treatment change decision in clinic showing how complicated these decisions are in the real world.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
20/PR/0587
Date of REC Opinion
24 Nov 2020
REC opinion
Further Information Favourable Opinion